|
|
Article: Celgene Corporation Reports Strong Operating Performance in Second Quarter as Total Sales Increase 100 Percent and Profits Rise.
- Article from:
- PR Newswire
- Article date:
- July 24, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Product Sales Driven by Increase of 93.4 Percent, year-over-year, in
THALOMID(R) Revenues and Reintroduction of ALKERAN(R)
* Quarterly Earnings of $0.03 per Diluted Share Exceeds Earnings
Consensus
* 2003 Full Year Financial Guidance Raised
* R&D Investment Increased to Accelerate REVIMID(TM) Regulatory Approval
Recent Highlights:
* Additional Clinical Data Demonstrated REVIMID Potential in Treating -
Myelodysplastic Syndromes (MDS) - Two MDS Studies Initiated
* Researchers Presented New Clinical Data on THALOMID From More Than 150
Clinical Trials Covering All Stages of Multiple Myeloma and Broad Range
of Solid Tumors
* ...